|
Spondylarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multimorbidity in Axial Spondyloarthropathy and Its Association with Disease Outcomes: Results from the Ankylosing Spondylitis Registry of Ireland Cohort.
|
31092715 |
2020 |
|
Spondylarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ten statements achieved consensus.Patients may be considered for subsidization of biologic therapy if they fulfill the Assessment of Spondyloarthritis International Society or modified New York criteria, with persistently active disease (defined either by Ankylosing Spondylitis Disease Activity Score ≥ 2.1 or Bath Spondylitis Disease Activity Index ≥ 4), despite 4 weeks of full-dose non-steroidal anti-inflammatory drugs and regular exercise.
|
31762225 |
2020 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
|
31436036 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The British Society for Rheumatology Biologics Register in Ankylosing Spondylitis has recruited patients meeting Assessment of Spondyloarthritis international Society criteria for axSpA from 83 centers.
|
30385702 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
HLA-B*27 positivity was associated with a prolonged course of disease, higher incidence of AAU (14.7% vs 2%, P = 0.015), family history of spondyloarthritis (21.1% vs 5.9%; P = 0.015) and higher erythrocyte sedimentation rate as compared to HLA-B*27 negative patients (P < 0.01).
|
30884197 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is prototype of SpA.
|
31741083 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS), a common type of spondyloarthropathy, is a chronic inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic pain; additionally, in more advanced cases, it can cause spine fusion.
|
31666997 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
|
31436026 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are classified as spondyloarthritis (SpA), a group of inflammatory rheumatic diseases with complex genetic etiology.
|
31781672 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
After adjustment for HLA-B*27 status, only NKC3 C/C remained linked to spondyloarthritis (adjusted OR = 0.14 (0.06‒0.33)).
|
30177859 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TNFi retention rates (Kaplan-Meier statistics), Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive disease (<1.3), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <40 mm and Assessment of SpondyloArthritis International Society responses (ASAS 20/40) were assessed at 6, 12 and 24 months.
|
31431486 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this Review, the relationship between AAU, SpA and the microbiome is discussed, with a focus on the major SpA risk gene HLA-B*27 and how it is associated with both intestinal tolerance and the loss of ocular immune privilege that can accompany AAU.
|
30301938 |
2018 |
|
Spondylarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the proportion of patients achieving the 20% and 40% improvement in the Assessment of Spondyloarthritis international Society criteria (ASAS20 and ASAS40) as well as Ankylosing Spondylitis Disease Activity Score (ASDAS) improvement and status scores at 1 year.
|
29449504 |
2018 |
|
Spondylarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients were included on the basis of active SpA with a Bath Ankylosing Spondylitis Disease Activity Index ≥ 4.
|
28649913 |
2018 |
|
Spondylarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cox regression models were used to estimate the association of baseline mRDCI with drug discontinuation and clinical outcomes, the achievement of clinical remission based on 28 joint-Disease Activity Score (DAS28) <2.6 for RA and PsA, and on Ankylosing Spondylitis-C-reactive protein Disease Activity Score (ASDAS-CRP) <1.3 for SpA.
|
30079593 |
2018 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genotyping of HLA-B*27 would shed light on our understanding of the pathogenesis of SpA.
|
28632339 |
2018 |
|
Spondylarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Statistically significant differences between the two treatment groups were observed for proportion of patients achieving ASAS40 (P = 0.0413, at week 8), ASAS5/6 (P = 0.0126), Ankylosing Spondylitis Disease Activity Score - C-reactive protein (CRP) inactive disease (P = 0.0093), Spondyloarthritis Research Consortium of Canada magnetic resonance imaging of sacroiliac joint scores (P = 0.0014), high-sensitivity CRP (P=0.032), and erythrocyte sedimentation rate (P = 0.0082).
|
27863065 |
2018 |
|
Spondylarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical and MRI remission definitions included Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS ID; score < 1.3) and Spondyloarthritis Research Consortium of Canada (SPARCC) MRI score < 2 for sacroiliac joints (SIJs), spine, or both.
|
29587851 |
2018 |
|
Spondylarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The HLA-B*27 allele group, which presents intracellular peptides to CD8+ T cells, is by far the strongest risk factor for spondyloarthritis.
|
29675414 |
2018 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Scotland Registry for Ankylosing Spondylitis collects data from clinically diagnosed patients with spondyloarthritis.
|
27899002 |
2017 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Natural HLA-B*2705 protein ligands with glutamine as anchor motif: implications for HLA-B27 association with spondyloarthropathy.
|
23430249 |
2013 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that HLA-B*2705 was the predominant subtype in Koreans with SpA; this finding is remarkable because other Asians such as the Han or the Japanese exclusively have the B*2704 subtype.
|
18493767 |
2008 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To examine whether and to what extent the intracellular trafficking features of HLA-B*2705, which is associated with the development of spondylarthritis (SpA), differ from those of HLA-B*2709 and HLA-B*0702, which are not associated with SpA.
|
17599742 |
2007 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis and related spondylarthritides are associated with HLA-B27, and also with intestinal inflammation, by unknown mechanisms.
|
16575857 |
2006 |
|
Spondylarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HLA B-27 subtypes in Turkish patients with spondyloarthropathy and healthy controls.
|
15665390 |
2004 |